Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens

被引:2
|
作者
Hariri, Nosaibah [1 ]
Hasteh, Farnaz [1 ]
Walavalkar, Vighnesh [1 ]
Roma, Andres A. [1 ]
Fadare, Oluwole [1 ]
机构
[1] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA
关键词
repeat testing; estrogen receptor; progesterone receptor; human epidermal growth factor receptor-2; IN-SITU HYBRIDIZATION; INTRATUMORAL HETEROGENEITY; CORE-NEEDLE; CLINICAL ONCOLOGY/COLLEGE; PROTEIN EXPRESSION; AMERICAN SOCIETY; HER2; DISCORDANCE; ER; RECOMMENDATIONS;
D O I
10.1097/PAI.0000000000000525
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
At some tertiary breast care centers, where many patients are referred from other institutions, it is routine to repeat testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2/neu) in excision specimens if these tests were performed on the preceding biopsy at the referring facility. The goal of this study is to assess the value of this practice. We documented results from ER, PR, and HER2 testing in 541 consecutive invasive breast cancers excised over a 2.5-year period and analyzed the subset (n=153) for which testing was performed on the excision specimen solely due to the fact that testing on the preceding biopsy was performed at an outside institution. The rates and directions of biopsy-to-excision change were as follows: ER [1.3% (2/153), 100% from (+) to (-)]; PR [4% (6/153), 83% from (+) to (-)]; HER2/neu assessed by immunohistochemistry [21% (29/137)]; HER2/neu assessed by fluorescence in situ hybridization [3.3% (2/61); 50% from amplified to nonamplified and 50% vice versa]. There were no ER(-) and PR(-) biopsy cases that became ER and/or PR(+) in the excision. By coordinate analysis for the hormone receptors [ie, ER and/or PR(+) being indicative of "hormone receptor" (HR) positivity], there were no cases that changed from HR(+) in the biopsy to HR(-) in the excision (or vice versa), which suggests that repeat testing for ER and PR in this setting is of limited value. In an analysis that incorporated both immunohistochemistry and in situ fluorescence hybridization results, there were 2 cases with a clinically significant biopsy-to-excision change in HER2/neu status in which that change was detected primarily because the excision was retested. These findings provide baseline data for formulating policies on whether repeat testing should routinely be performed in the described scenario.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [1] Advances in Variations of Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor-2 Status in Metastatic Breast Cancer
    Yuan Yuan
    Zhang Lili
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2013, 1 (02): : 55 - 60
  • [2] Human epidermal growth factor receptor 2 testing in breast cancer
    Nielsen, Kirsten Vang
    Jorgensen, Jan T.
    Schonau, Andreas
    Oster, Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 4020 - 4020
  • [3] Human epidermal growth factor receptor 2 testing in breast cancer
    Nielsen, Kirsten Vang
    Jorgensen, Jan T.
    Schonau, Andreas
    Oster, Anne
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2007, 131 (09) : 1330 - 1330
  • [4] Association of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression with Breast Cancer Metastasis in Iran
    Jafari, Seyed Hamed
    Jahanmir, Armaghan
    Bahramvand, Yaser
    Tahmasebi, Sedigheh
    Dallaki, Manoochehr
    Nasrollahi, Elham
    IRANIAN JOURNAL OF MEDICAL SCIENCES, 2022, 47 (01) : 40 - 47
  • [5] Expressional Correlation of Human Epidermal Growth Factor Receptor 2, Estrogen/Progesterone Receptor and Protein 53 in Breast Cancer
    Panahi, Marzieh
    Saki, Najmaldin
    Ashourzadeh, Sara
    Rahim, Fakher
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (06) : 3699 - 3703
  • [6] Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer
    Kim, HJ
    Cui, XJ
    Hilsenbeck, SG
    Lee, AV
    CLINICAL CANCER RESEARCH, 2006, 12 (03) : 1013S - 1018S
  • [7] The diagnostic value of BI-RADS grade 3 to 5 for breast masses is correlated with the expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2
    He, Tiejun
    Shi, Tiemei
    Luo, Wendong
    Ju, Yabo
    Li, Ran
    MEDICINE, 2023, 102 (26) : E33208
  • [8] Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression Rates in Invasive Breast Carcinoma
    Mais, Daniel D.
    Nazarullah, Alia N.
    Guidi, Anthony J.
    Dintzis, Suzanne
    Blond, Barbara J.
    Long, Thomas A.
    Coulter, Suzanne N.
    Brown, Richard W.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2025, 149 (01) : 8 - 13
  • [9] Estrogen receptor and human epidermal growth factor receptor-2 quantification and efficacy to trastuzumab
    Nuciforo, Paolo
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S569 - S571
  • [10] Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country
    S. Subramaniam
    N. Bhoo-Pathy
    N. A. Taib
    G. H. Tan
    M. H. See
    S. Jamaris
    G. F. Ho
    L. M. Looi
    C. H. Yip
    World Journal of Surgery, 2015, 39 : 2450 - 2458